- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07229157
Effekten av Maridebart Cafraglutide på hjertets elektriske aktivitet
En fase 1, randomisert, dobbeltblind, placebo- og positivkontrollert, parallell gruppestudie med nested crossover-sammenligning for å vurdere effekten av Maridebart Cafraglutide på QT/QTc-intervaller hos deltakere med overvekt eller fedme
The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Daytona Beach, Florida, Forente stater, 32117-5116
- Fortrea Clinical Research Unit - Daytona Beach
-
-
Texas
-
Dallas, Texas, Forente stater, 75247-4968
- Fortrea Clinical Research Unit - Dallas
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria
To take part in the trial, participants must meet all of the following:
-
Provide signed and dated informed consent before any trial procedures.
-
Be able to understand the trial requirements, sign the consent form, and follow trial restrictions.
-
Male or female, of any race, between 18 and 60 years old (inclusive).
- Females must not be pregnant or breastfeeding.
- Males and females who could become pregnant must agree to use effective birth control as specified in the protocol.
-
Body mass index (BMI) between 25.0 and 35.0 kg/m^2 (inclusive).
-
No major changes in diet or lifestyle in the past 3 months, based on self-report.
-
Stable body weight (less than 5 kg change) in the past 3 months, based on self-report.
-
Blood potassium, calcium, and magnesium within the normal range at screening and at check-in for the first treatment period.
-
Participants with controlled high blood pressure, cholesterol problems, or hypothyroidism on stable treatment for at least 3 months may be included (except for medicines known to affect heart rhythm or interact with moxifloxacin). Other mild, stable health conditions may be allowed with approval from the investigator and medical monitor.
Exclusion Criteria
Participants will not be able to take part if they meet any of the following:
Medical Conditions
-
Any significant medical condition or abnormal test result that, in the opinion of the investigator, could pose a risk or interfere with trial participation.
-
History of diabetes (any type, except past gestational diabetes), or Haemoglobin A1c (HbA1c) ≥ 6.5% at screening.
-
History of pancreatitis within the past year, or high blood tests suggesting pancreatic problems (lipase/amylase > 2× normal, or fasting triglycerides > 500 mg/dL).
-
Liver enzymes (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) more than 2× the upper limit of normal.
-
Kidney function (estimated glomerular filtration rate [eGFR]) < 70 mL/min/1.73 m^2.
-
Cancer within the last 5 years (except treated nonmelanoma skin cancers or in situ cervical/breast lesions).
-
Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
-
Uncontrolled thyroid disease (abnormal thyroid-stimulating hormone [TSH] outside 0.4-6.0 mIU/L).
-
Contraindications to moxifloxacin, including history of tendon disorders with quinolone use.
-
History of gastrointestinal surgery or disease that may affect absorption of oral drugs (other than uncomplicated appendectomy or hernia repair).
-
Inability to swallow pills.
-
History of significant esophageal, stomach, or bowel disorders (eg, ulcers, bleeding, Crohn's disease, ulcerative colitis, irritable bowel syndrome, gastroparesis).
-
Current or recent suicidal thoughts (per Columbia Suicide Severity Rating Scale [C-SSRS]).
-
Lifetime history of suicide attempt or behavior.
-
Major depressive disorder within the past 2 years.
-
History of other serious psychiatric disorders (eg, schizophrenia, bipolar disorder).
-
High depression score (patient health questionnaire-9 [PHQ-9] ≥ 15).
-
History or current signs of heart disease (eg, heart attack, congenital defects, valve disease, angina, bypass or stent).
-
History of ischemic optic neuropathy (eye damage from poor blood flow).
-
Diagnosis of sleep apnea. Diagnostic Tests
-
Positive test for human immunodeficiency virus (HIV).
-
Positive test for hepatitis B or C (exceptions apply for prior vaccination or resolved infection).
-
Abnormal vital signs: average blood pressure > 140/90 mmHg or < 90/50 mmHg, or heart rate > 110 or < 40 bpm.
-
Abnormal ECG findings at screening or check-in, including:
- QTcF > 450 ms (males) or > 470 ms (females).
- QRS > 120 ms, PR > 220 ms, AV block (2nd or 3rd degree).
- Findings that make QTc measurement unreliable.
- Risk factors for dangerous arrhythmias (eg, heart failure, low potassium, long QT syndrome).
- Clinically significant arrhythmias. Medications
-
Use of drugs that affect absorption, metabolism, or elimination within 30 days of dosing.
-
Use of drugs known to prolong QT/QTc within 30 days of dosing.
-
Use of prescription drugs (other than hormone replacement or contraception) within 14 days of dosing.
-
Use of long-acting/slow-release medicines still active within 14 days of dosing.
-
Use of non-prescription products (vitamins, supplements, herbal products) within 7 days of dosing.
-
Use of glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) receptor agonists/antagonists within 3 months of check-in.
Other Clinical Trial Experience
-
Participation in another investigational drug trial within 30 days or 5 drug half-lives (whichever is longer).
-
Previous exposure to maridebart cafraglutide in this or another trial. Lifestyle
-
Alcohol use > 21 units/week (men) or > 14 units/week (women).
-
Alcohol use within 48 hours before check-in.
-
Positive drug screen or alcohol test at screening or check-in.
-
History of alcohol or drug abuse within 1 year.
-
Use of tobacco/nicotine products within 3 months, or positive cotinine test.
-
Use of caffeine within 48 hours of screening or check-in.
-
Consumption of grapefruit, Seville orange, or related products within 7 days of check-in.
-
Consumption of poppy seed-containing foods within 7 days of check-in. Other
-
Receipt of blood products within 2 months before check-in.
-
Blood donation within 3 months; plasma donation within 2 weeks; platelet donation within 6 weeks.
-
Poor veins for blood draws.
-
Any other reason, in the opinion of the investigator, the participant should not take part.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Group 1
In treatment period 1, participants will receive placebo for moxifloxacin. In treatment period 2, participants will receive maridebart cafraglutide. In treatment period 3, participants will receive placebo for moxifloxacin. |
Participants will receive maridebart cafraglutide SC.
Andre navn:
Participants will receive placebo for moxifloxacin orally. |
|
Eksperimentell: Group 2A
In treatment period 1, participants will receive moxifloxacin. In treatment period 2, participants will receive placebo for maridebart cafraglutide. In treatment period 3, participants will receive placebo for moxifloxacin. |
Participants will receive placebo for moxifloxacin orally. Participants will receive moxifloxacin orally. Participants will receive placebo for maridebart cafraglutide SC. |
|
Eksperimentell: Group 2B
In treatment period 1, participants will receive placebo for moxifloxacin. In treatment period 2, participants will receive placebo for maridebart cafraglutide. In treatment period 3, participants will receive moxifloxacin. |
Participants will receive placebo for moxifloxacin orally. Participants will receive moxifloxacin orally. Participants will receive placebo for maridebart cafraglutide SC. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in QTcF for Maridebart Cafraglutide
Tidsramme: Up to Day 171
|
Change from baseline in QTcF for maridebart cafraglutide will be the dependent variable for calculation of model-derived placebo-corrected, change from baseline in QTcF after maridebart cafraglutide dosing. |
Up to Day 171
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Areal under konsentrasjonstidskurven over doseringsintervallet (AUCtau) for Maridebart Cafraglutide
Tidsramme: Opp til dag 171
|
Opp til dag 171
|
|
|
Maksimal observert konsentrasjon (Cmax) av Maridebart Cafraglutid
Tidsramme: Opp til dag 171
|
Opp til dag 171
|
|
|
Kategoriske avvik for QTcF
Tidsramme: Opp til dag 171
|
Opp til dag 171
|
|
|
Kategoriske avvikere for HR
Tidsramme: Opp til dag 171
|
Opp til dag 171
|
|
|
Kategoriske unntak for PR
Tidsramme: Opp til dag 171
|
Opp til dag 171
|
|
|
Kategoriske Unntak for QRS
Tidsramme: Opptil dag 171
|
Opptil dag 171
|
|
|
Antall deltakere med behandlingsrelaterte endringer i elektrokardiogram (EKG) morfologi
Tidsramme: Opp til dag 171
|
Opp til dag 171
|
|
|
Antall deltakere med behandlingsrelaterte bivirkninger og alvorlige bivirkninger
Tidsramme: Frem til dag 232
|
Frem til dag 232
|
|
|
Antall deltakere med antistoffdannelse mot maridebart cafraglutide
Tidsramme: Frem til dag 232
|
Frem til dag 232
|
|
|
Change from Baseline in Heart Rate
Tidsramme: Up to Day 171
|
Change from baseline in heart rate will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in HR for the by-time point analysis. |
Up to Day 171
|
|
Change from Baseline in PR Interval
Tidsramme: Up to Day 171
|
Change from baseline in PR Interval will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in PR for the by-time point analysis. |
Up to Day 171
|
|
Change from Baseline in QRS Duration
Tidsramme: Up to Day 171
|
Change from baseline in QRS Duration will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in QRS for the by-time point analysis. |
Up to Day 171
|
|
Change from Baseline in QTcF for Moxifloxacin
Tidsramme: Up to Day 171
|
Change from baseline in QTcF for moxifloxacin will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in QTcF after moxifloxacin dosing for both the assay sensitivity and by-time point analysis. |
Up to Day 171
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: MD, Amgen
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Ernæringsforstyrrelser
- Overernæring
- Kroppsvekt
- Patologiske tilstander, tegn og symptomer
- Ernæringsmessige og metabolske sykdommer
- Tegn og symptomer
- Overvektig
- Overvekt
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Fluorokinoloner
- 4-kvinoloner
- Kinoloner
- Kinoliner
- Moxifloxacin
Andre studie-ID-numre
- 20250003
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD-delingstidsramme
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Tilgangskriterier for IPD-deling
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .